Protagonist Therapeutics, Inc.
PTGX
Classificação em ações
#2189
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Preço da ação
$139.43
Valor de mercado
$9.02B
Variação (1 dia)
0.98%
Variação (1 ano)
89.70%
País
US
Negociar Protagonist Therapeutics, Inc. (PTGX)
Categoria
Healthcare
Histórico de preços das ações de Protagonist Therapeutics, Inc. (PTGX)
Preço de fecho mais alto: $138.63 em 2026-10-01
Preço de fecho mais baixo: $11.34 em 2016-08-01
Preço de fecho mais baixo: $11.34 em 2016-08-01
Histórico de preços das ações da Protagonist Therapeutics, Inc. de 2016 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | 21.88% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $532.09 | 24.77% |
US
|
|
| $236.63 | 781.30% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.94 | 9.31% |
NL
|
|
| $291.42 | 2.39% |
BE
|
